» Articles » PMID: 27008872

Detection of Pneumocystis Jirovecii by Quantitative PCR To Differentiate Colonization and Pneumonia in Immunocompromised HIV-Positive and HIV-Negative Patients

Overview
Specialty Microbiology
Date 2016 Mar 25
PMID 27008872
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Pneumocystis jirovecii pneumonia (PCP) is an acute and life-threatening lung disease caused by the fungus Pneumocystis jirovecii The presentation of PCP in HIV-positive patients is well-known and consists of a triad of dyspnea, fever, and cough, whereas the presentation of PCP in HIV-negative patients is atypical and consists of a sudden outbreak, O2 desaturation, and a rapid lethal outcome without therapy. Despite the availability of direct and indirect identification methods, the diagnosis of PCP remains difficult. The cycle threshold (CT) values obtained by quantitative PCR (qPCR) allow estimation of the fungal burden. The more elevated that the fungal burden is, the higher the probability that the diagnosis is pneumonia. The purposes of the present study were to evaluate the CT values to differentiate colonization and pneumonia in a population of immunocompromised patients overall and patients stratified on the basis of their HIV infection status. Testing of bronchoalveolar lavage (BAL) fluid samples from the whole population of qPCR-positive patients showed a mean CT value for patients with PCP of 28 (95% confidence interval [CI], 26 to 30) and a mean CT value for colonized patients of 35 (95% CI, 34 to 36) (P < 10(-3)). For the subgroup of HIV-positive patients, we demonstrated that a CT value below 27 excluded colonization and a CT value above 30 excluded PCP with a specificity of 100% and a sensitivity of 80%, respectively. In the subgroup of HIV-negative patients, we demonstrated that a CT value below 31 excluded colonization and a CT value above 35 excluded PCP with a specificity of 80% and a sensitivity of 80%, respectively. Thus, qPCR of BAL fluid samples is an important tool for the differentiation of colonization and pneumonia in P. jirovecii-infected immunocompromised patients and patients stratified on the basis of HIV infection status with different CT values.

Citing Articles

Diagnostic tests performance in detecting Pneumocystis jirovecii: A systematic review and meta-analysis.

Zhang L, Zheng C, Sun Y, Chen X, Wang Y, Xiang H Eur J Clin Microbiol Infect Dis. 2025; .

PMID: 39900713 DOI: 10.1007/s10096-025-05051-6.


A Systematic Literature Review to Determine Gaps in Diagnosing Suspected Infection in Solid Organ Transplant Recipients.

Park S, Goldman J, Levine D, Haidar G Open Forum Infect Dis. 2025; 12(1):ofaf001.

PMID: 39877399 PMC: 11773193. DOI: 10.1093/ofid/ofaf001.


Quantitative real time PCR for distinction between infection/colonization in hospitalized patients.

Rouhi F, Erami M, Rastgufar S, Jahani M, Aboutalebian S, Soltani S Front Cell Infect Microbiol. 2024; 14:1426200.

PMID: 39380728 PMC: 11458531. DOI: 10.3389/fcimb.2024.1426200.


Development of a clinical risk score for the prediction of Pneumocystis jirovecii pneumonia in hospitalised patients.

Mappin-Kasirer B, Del Corpo O, Gingras M, Hass A, Hsu J, Costiniuk C BMC Infect Dis. 2024; 24(1):1032.

PMID: 39333914 PMC: 11429489. DOI: 10.1186/s12879-024-09957-y.


Identifying optimal serum 1,3-β-D-Glucan cut-off for diagnosing Pneumocystis Jirovecii Pneumonia in non-HIV patients in the intensive care unit.

Li Y, Chen Y, Li S, Dong R, Yang Q, Peng J BMC Infect Dis. 2024; 24(1):1015.

PMID: 39304817 PMC: 11414112. DOI: 10.1186/s12879-024-09873-1.


References
1.
Thomas M, Rupali P, Woodhouse A, Ellis-Pegler R . Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients. Scand J Infect Dis. 2009; 41(11-12):862-8. DOI: 10.3109/00365540903214256. View

2.
Goto N, Oka S . Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis. 2011; 13(6):551-8. DOI: 10.1111/j.1399-3062.2011.00691.x. View

3.
Thomas Jr C, Limper A . Pneumocystis pneumonia. N Engl J Med. 2004; 350(24):2487-98. DOI: 10.1056/NEJMra032588. View

4.
Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M . Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromized patients with and without HIV infection. Respirology. 2009; 15(1):126-31. DOI: 10.1111/j.1440-1843.2009.01660.x. View

5.
Ognibene F, Shelhamer J, Hoffman G, Kerr G, Reda D, Fauci A . Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med. 1995; 151(3 Pt 1):795-9. DOI: 10.1164/ajrccm/151.3_Pt_1.795. View